Ascend Wellness Holdings (AAWH) Cost of Revenue (2020 - 2026)
Ascend Wellness Holdings (AAWH) recorded quarterly Cost of Revenue of $72.1 million in Q1 2026, down 4.47% quarter-over-quarter from $75.4 million in Q4 2025, and down 18.53% on a YoY basis from $88.4 million in Q1 2025.
Ascend Wellness Holdings (AAWH) Cost of Revenue (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Cost of Revenue history runs 7 years deep, the most recent figure standing at $72.1 million for Q1 2026.
- In Q1 2026, Cost of Revenue fell 18.53% year-over-year to $72.1 million; the TTM figure through Mar 2026 stood at $314.5 million (down 16.23% YoY), while the FY2025 annual figure was $330.9 million, down 12.32% from the prior year.
- Cost of Revenue was $72.1 million for Q1 2026 at Ascend Wellness Holdings, down from $75.4 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $100.0 million in Q2 2024 to a low of $61.6 million in Q1 2022.
- Historically, Cost of Revenue has averaged $83.2 million across 5 years, with a median of $85.9 million in 2025.
- The sharpest annual moves came in 2022 and 2026: Cost of Revenue jumped 69.02% in 2022, then fell 18.53% in 2026.
- A 5-year view of Cost of Revenue shows it stood at $70.6 million in 2022, then jumped by 31.21% to $92.6 million in 2023, then decreased by 3.76% to $89.1 million in 2024, then fell by 15.39% to $75.4 million in 2025, then fell by 4.47% to $72.1 million in 2026.
- The last three Cost of Revenue figures came in at $72.1 million (Q1 2026), $75.4 million (Q4 2025), and $81.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 696.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 641.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 133.40 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 34.44 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 13.80 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 586.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 155.56 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 52.68 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 222.00 Mn |
| 10 | Ascend Wellness Holdings | - | - | 44.88 Mn | 72.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.05 Mn |
| Mar 31, 2026 | 72.05 Mn |
| Dec 31, 2025 | 75.42 Mn |
| Dec 31, 2025 | 75.42 Mn |
| Sep 30, 2025 | 81.13 Mn |
| Sep 30, 2025 | 81.13 Mn |
| Jun 30, 2025 | 85.91 Mn |
| Jun 30, 2025 | 85.91 Mn |
| Mar 31, 2025 | 88.44 Mn |
| Mar 31, 2025 | 88.44 Mn |
| Dec 31, 2024 | 89.14 Mn |
| Dec 31, 2024 | 89.14 Mn |
| Sep 30, 2024 | 97.92 Mn |
| Sep 30, 2024 | 97.92 Mn |
| Jun 30, 2024 | 99.96 Mn |
| Jun 30, 2024 | 99.96 Mn |
| Mar 31, 2024 | 90.37 Mn |
| Mar 31, 2024 | 90.37 Mn |
| Dec 31, 2023 | 92.62 Mn |
| Dec 31, 2023 | 92.62 Mn |